Get the Stockscreener App
115.96
5.80%
6.36
Dianthus Therapeutics Inc stock is traded at $115.96, with a volume of 903.09K.
It is up +5.80% in the last 24 hours and up +14.49% over the past month.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
See More
Previous Close:
$109.60
Open:
$108.96
24h Volume:
903.09K
Relative Volume:
0.89
Market Cap:
$6.49B
Revenue:
$1.34M
Net Income/Loss:
$-173.66M
P/E Ratio:
-28.02
EPS:
-4.1385
Net Cash Flow:
$-130.49M
1W Performance:
+6.46%
1M Performance:
+14.49%
6M Performance:
+144.64%
1Y Performance:
+472.64%
1-Day Range:
$108.77
$116.47
1-Week Range:
$106.24
$116.47
52-Week Range:
$19.84
$116.47
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
115.96 | 6.29B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-10-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics SVP Adam M. Veness Exercises 15,000 Stock Options at $18.17 Each - Kalkine Media
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 114.64 USD - Investing.com
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake - Stock Titan
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Dianthus therapeutics director Simon Read sells $304k in stock By Investing.com - Investing.com Australia
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock By Investing.com - Investing.com Nigeria
Dianthus therapeutics director Simon Read sells $304k in stock - Investing.com
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock - Investing.com
Anne Mcgeorge Sells 7,750 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells 16,167 Shares of Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells $424,313.10 in Stock - MarketBeat
Dianthus Therapeutics Insider Sold Shares Worth $844,822, According to a Recent SEC Filing - marketscreener.com
DNTH insider Adam M. Veness plans Rule 144 sale of 16,167 shares - Stock Titan
Assenagon Asset Management S.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - MarketBeat
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares By Investing.com - Investing.com Australia
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares - Investing.com
Dianthus Therapeutics(DNTH.US) Officer Sells US$17.95 Million in Common Stock - Moomoo
Marino Garcia Sells 166,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 7, 2026) - Stock Titan
Dynathera (DNTH) insider schedules 3,833-share stock sale under Rule 144 - Stock Titan
Dnth Holdings (DNTH) plans Rule 144 resale of 126,000 shares via Morgan Stanley - Stock Titan
Dianthus Therapeutics (DNTH): T. Rowe Price reports 12.1% ownership stake - Stock Titan
Dianthus Therapeutics (DNTH): T. Rowe Price reports 7.1% stake in common stock - Stock Titan
Dianthus Therapeutics CEO Marino Garcia reports disposal of 166,000 common shares worth $17.97 million - Bitget
Dianthus Therapeutics (DNTH) Stock Analysis: A Promising Biotech with 19.46% Potential Upside - directorstalkinterviews.com
The Manufacturers Life Insurance Company Grows Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DIANTHUS THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $131 FROM $125 - webull.com
DIANTHUS THERAPEUTICS INC : WEDBUSH RAISES TARGET PRICE TO $122 FROM $105 - webull.com
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $128.00 - MarketBeat
HC Wainwright Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DIANTHUS THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $158 FROM $130 - Bitget
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $122 to $150 - Moomoo
Dianthus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Dianthus Therapeutics, Inc. Stock 12‑Month Price Target Raised to $133.79, Implies 21% Upside - TradingView
Dianthus Therapeutics (NASDAQ:DNTH) Given New $122.00 Price Target at Wedbush - MarketBeat
DNTH SWOT Analysis: Financial Strength and Overvaluation Concerns Revealed in 10-Q Filing - GuruFocus
Dianthus Therapeutics (NASDAQ:DNTH) Posts Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q2 License Revenue $761K - marketscreener.com
Dianthus Therapeutics reports Q2 2026 net loss $50.2M, cash ~$1.2B; advances claseprubart Phase 3 - TradingView
Dianthus Therapeutics 2Q 2026: Revenue $0.8M, Net loss $(50.2M), EPS $(0.90) — 10-Q Summary - TradingView
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results - The Manila Times
Dianthus Therapeutics Q2 net loss widens as R&D costs rise - TradingView
Dianthus Therapeutics (NASDAQ: DNTH) raises $719M to fund pipeline - Stock Titan
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases - The Manila Times
Dianthus Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):